kidney-nephrology-2017-scientifictracks-abstracts

27 / 33

Page 64
Notes:
conferenceseries.com
Volume 3, Issue 3 (Suppl) J Kidney, an open access journal
ISSN:2472-1220 Kidney & Nephrology 2017
August 28-30, 2017
August 28-30, 2017 Philadelphia, USA
15th Annual Congress on
Kidney: Nephrology & Therapeutics
Kenjiro Honda, J Kidney 2017, 3:3 (Suppl)
DOI: 10.4172/2472-1220-C1-002
Recent topics of autosomal dominant polycystic kidney disease (ADPKD)
Kenjiro Honda
The University of Tokyo Graduate School of Medicine, Japan
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common hereditary kidney diseases that
develop end-stage kidney disease. Usage of renin-angiotensin-aldosterone system inhibitors and educational campaign
such as salt restriction and metabolic syndrome have successfully delayed initiation of dialysis in the other kidney diseases.
However, ADPKD patients have obtained littele benefit from these appearance of medicine or activities. As a result, ADPKD
now requires dialysis at a younger age than the other kidney diseases. Tolvaptan is the first drug that directly inhibits growth
of kidney cysts. TEMPO 3:4 study clinically showed efficacy and safety of tolvaptan treatment among ADPKD patients with
creatinine clearance more than 60 mL/min. This medicine improved decline of kidney function as well as enlargement of total
kidney volume. Polyuria is frequently present, and tolvaptan requires sufficient fluid intake. According to TEMPO 3:4 study,
tolvaptan can be administered to ADPKD patients with chronic kidney disease (CKD) G1-G4 since 2014 in Japan. Tolvaptan
has been administered to ore than 1,000 ADPKD patients. Approval of indication including CKD G3 and G4 resulted in the
current situation that CKD G3 and G4 is dominant in tolvaptan-treated patients. I will introduce therapeutic effect and amount
of fluid intake and urine volume in tolvaptan treatment.
Biography
Kenjiro Honda graduated from The University of Tokyo in 2005, and completed his PhD from The University of Tokyo Graduate School of Medicine in 2013. His
work is genetics in kidney including ADPKD, and peripheral arterial disease. He is now an Associate Professor in Department of Nephrology and Endocrinology,
The University of Tokyo Graduate School of Medicine.